MIDRP Overview History & Achievements Current Research Efforts External Programs

Program Overview:
Dengue is the most significant arthropod-borne viral disease of man and the most geographically widespread of the arthropod-borne viruses. Each year it is estimated there are 50-100 million dengue virus (DENV) infections, occurring in over 100 countries, resulting in over 25,000 deaths. Dengue is epidemic or endemic in virtually every country in the tropics and endemic in subtropical regions of the world where military personnel are/may be stationed or deployed, including Central and South America, the Caribbean, Southeast Asia, Africa, and the western Pacific region. The National Center for Medical Intelligence (NCMI) has incident rates as high as 10% or higher/month in parts of SOUTHCOM (e.g. Colombia) and PACOM (e.g. Thailand). The reposting of dengue in AFRICOM countries is poor not allowing for a good assessment of incidence; however, it does occur over the entire equatorial belt. Dengue epidemics can be explosive, with high attack rates, morbidity, and with potential to rapidly incapacitate large numbers of personnel, argues that US Forces need some form of protection against this disease to prevent the asymmetrical impact to combat, sustainment, and humanitarian operations, resulting from never exposed US Forces operating against forces previously exposed and likely protected against dengue fever.

There are currently numerous efforts in the US Army Medical Research and Materiel Command (USAMRMC), private industry, academic centers, and other government organizations to develop a dengue vaccine. Program Area S seeks to develop a tetravalent dengue vaccine to protect the warfighter against dengue disease. The program will facilitate this with a balanced portfolio of basic science discovery, clinical readout improvement and development and developing robust field sites capable of conducting clinical efficacy trials in dengue endemic counties while conducting epidemiological and surveillance studies to generate reagents and data to support the vaccine development program.

HIV | Flavivirus Vaccines | Lethal Virus Countermeasures